Avicanna Announces Results of Annual General Meeting

Core Points - Avicanna Inc. announced that all management nominees were elected as directors during the Annual General Meeting of Shareholders held on June 30, 2025 [1] - The shareholders approved the reappointment of Ramirez Jimenez International CPAs as auditors for the upcoming year [3] Company Overview - Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products for the global medical and pharmaceutical markets [4] - The company has a scientific platform that includes R&D and clinical development, leading to over thirty proprietary, evidence-based finished products [4] Product and Service Offerings - The RHO Phyto™ formulary offers a range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying cannabinoid ratios, currently available nationwide in Canada and expanding internationally [6] - MyMedi.ca is a medical cannabis care platform aimed at enhancing the patient journey, featuring a diverse product portfolio and bilingual pharmacist-led support programs [6] - Avicanna has developed a pipeline of proprietary cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [6] - The company’s subsidiary, Santa Marta Golden Hemp SAS, supplies high-quality CBD, THC, and CBG for various applications, forming part of Avicanna's supply chain [6]